tiprankstipranks
Trending News
More News >

Argenica Therapeutics Issues New Shares Following Option Exercise

Story Highlights
Argenica Therapeutics Issues New Shares Following Option Exercise

Don’t Miss TipRanks’ Half-Year Sale

The latest update is out from Argenica Therapeutics Ltd ( (AU:AGN) ).

Argenica Therapeutics Limited has issued 10,522 fully paid ordinary shares following the exercise of unlisted options, with a $0.65 exercise price. This move is part of the company’s compliance with the Corporations Act, allowing these shares to be sold without disclosure under certain exemptions, potentially enhancing liquidity and investor engagement.

The most recent analyst rating on (AU:AGN) stock is a Buy with a A$1.14 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.

More about Argenica Therapeutics Ltd

Argenica Therapeutics Limited operates within the biotechnology industry, focusing on the development of novel therapeutics. The company is primarily engaged in creating treatments aimed at protecting brain cells and improving recovery following neurological conditions such as stroke.

Average Trading Volume: 94,515

Technical Sentiment Signal: Buy

See more data about AGN stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1